Ten takeaways from the AACR Annual Meeting

This year’s American Association for Cancer Research Annual Meeting featured several potentially practice-changing studies, including many that evaluated novel immunotherapy regimens and assessed biomarkers that may predict treatment response.

HemOnc Today presents 10 updates from the meeting that may affect your practice.

  • The addition of the anti-PD-1 therapy pembrolizumab (Keytruda, Merck) to chemotherapy significantly improved outcomes among patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer who did not harbor EGFR or ALK alterations, according to results of the phase 3 KEYNOTE-189 trial. Read more.
  • Immunotherapy with nivolumab (Opdivo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) significantly prolonged PFS compared with standard chemotherapy among patients with newly diagnosed advanced non-small cell lung cancer with high tumor mutational burden, according to results of the randomized phase 3 CheckMate -227 trial. Read more.
  • Nivolumab continued to confer a significant OS benefit compared with investigator’s choice of therapy among patients with recurrent or metastatic head and neck squamous cell carcinoma, according to long-term data from the phase 3 CheckMate 141 trial. Read more.
  • Patients with stage III melanoma at high risk for recurrence after surgery demonstrated significantly reduced risk for recurrence after 1 year of treatment with pembrolizumab, according to results from the KEYNOTE-054/EORTC 1325. Read more.
  • Calcium channel blockers appeared associated with increased risk for pancreatic cancer among postmenopausal women. Read more.
  • The addition of abemaciclib (Eli Lilly) to initial treatment with a nonsteroidal aromatase inhibitor appeared effective for women with hormone receptor-positive, HER-2-negative advanced breast cancer, according to results of the phase 3 MONARCH 3 study. Read more.
  • The addition of atezolizumab (Tecentriq, Genentech) to bevacizumab (Avastin, Genentech) plus chemotherapy extended PFS for patients with non-small cell lung cancer, according to results from the IMpower150 study. Read more.
  • The addition of the highly selective IDO1 inhibitor epacadostat (Incyte) to the PD-L1 inhibitor durvalumab (Imfinzi, AstraZeneca) appeared safe for patients with advanced solid tumors, including pancreatic cancer, melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma. Read more.
  • Children with nonchromosomal birth defects demonstrated significantly higher risk for certain childhood cancers. Read more.
  • The combination of pembrolizumab and CMP-001 (Checkmate Pharmaceuticals), an intratumoral toll-like receptor 9 agonist, demonstrated antitumor activity among patients with metastatic melanoma resistant to PD-1 checkpoint inhibition. Read more.

This year’s American Association for Cancer Research Annual Meeting featured several potentially practice-changing studies, including many that evaluated novel immunotherapy regimens and assessed biomarkers that may predict treatment response.

HemOnc Today presents 10 updates from the meeting that may affect your practice.

  • The addition of the anti-PD-1 therapy pembrolizumab (Keytruda, Merck) to chemotherapy significantly improved outcomes among patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer who did not harbor EGFR or ALK alterations, according to results of the phase 3 KEYNOTE-189 trial. Read more.
  • Immunotherapy with nivolumab (Opdivo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) significantly prolonged PFS compared with standard chemotherapy among patients with newly diagnosed advanced non-small cell lung cancer with high tumor mutational burden, according to results of the randomized phase 3 CheckMate -227 trial. Read more.
  • Nivolumab continued to confer a significant OS benefit compared with investigator’s choice of therapy among patients with recurrent or metastatic head and neck squamous cell carcinoma, according to long-term data from the phase 3 CheckMate 141 trial. Read more.
  • Patients with stage III melanoma at high risk for recurrence after surgery demonstrated significantly reduced risk for recurrence after 1 year of treatment with pembrolizumab, according to results from the KEYNOTE-054/EORTC 1325. Read more.
  • Calcium channel blockers appeared associated with increased risk for pancreatic cancer among postmenopausal women. Read more.
  • The addition of abemaciclib (Eli Lilly) to initial treatment with a nonsteroidal aromatase inhibitor appeared effective for women with hormone receptor-positive, HER-2-negative advanced breast cancer, according to results of the phase 3 MONARCH 3 study. Read more.
  • The addition of atezolizumab (Tecentriq, Genentech) to bevacizumab (Avastin, Genentech) plus chemotherapy extended PFS for patients with non-small cell lung cancer, according to results from the IMpower150 study. Read more.
  • The addition of the highly selective IDO1 inhibitor epacadostat (Incyte) to the PD-L1 inhibitor durvalumab (Imfinzi, AstraZeneca) appeared safe for patients with advanced solid tumors, including pancreatic cancer, melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma. Read more.
  • Children with nonchromosomal birth defects demonstrated significantly higher risk for certain childhood cancers. Read more.
  • The combination of pembrolizumab and CMP-001 (Checkmate Pharmaceuticals), an intratumoral toll-like receptor 9 agonist, demonstrated antitumor activity among patients with metastatic melanoma resistant to PD-1 checkpoint inhibition. Read more.

    See more from American Association for Cancer Research Annual Meeting